查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
銅綠假單胞菌治療市場：按治療類型、藥劑、給藥途徑、分銷渠道、國家、地區 - 行業分析、市場規模、市場份額、預測 2023-2030
市場調查報告書
商品編碼
1290842

銅綠假單胞菌治療市場：按治療類型、藥劑、給藥途徑、分銷渠道、國家、地區 - 行業分析、市場規模、市場份額、預測 2023-2030

Pseudomonas Aeruginosa Infection Treatment Market with COVID-19 Impact Analysis, By Treatment Type, Drug, Route Of Administration, Distribution channel, Country, & Region-Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 389 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年銅綠假單胞菌藥物市場規模將達到16.078億美元，2023年至2030年復合年增長率為6.8%

銅綠假單胞菌感染藥物市場 - 市場動態

消費者對銅綠假單胞菌治療的認識不斷增強，推動了市場需求

消費者對銅綠假單胞菌治療的認識的提高肯定會對相關產品和服務的市場需求產生積極影響。消費者意識的提高還可以激發對對抗銅綠假單胞菌的研發工作的興趣和投資。消費者意識也將導致對支持性護理和患者參與服務的需求增加。對銅綠假單胞菌治療的需求是由多種因素驅動的，包括銅綠假單胞菌感染患病率的增加和抗生素耐藥性的上升。對銅綠假單胞菌血流感染的回顧性分析證實，銅綠假單胞菌 (PA) 導致全世界 10-15% 的醫院感染。

銅綠假單胞菌感染治療市場 - 主要見解

  • 由於可持續增長意識的增強，預計銅綠假單胞菌感染治療行業將以顯著的速度增長
  • 根據治療細分，預計聯合療法將在 2022 年佔據最大的市場份額
  • 按藥物類型分，2022年頭孢菌素類將成為主要類型
  • 從給藥途徑來看，2022年以靜脈給藥為主。
  • 從分銷渠道來看，2022年醫院是主導類型。
  • 按地區劃分，北美為2022年主要收入來源

銅綠假單胞菌感染治療市場細分分析：

全球銅綠假單胞菌治療市場根據治療類型、藥物類型、給藥途徑、分銷渠道和區域進行細分。

市場按治療類型分為三組：單一療法和聯合療法聯合療法佔據市場主導地位。對於治療嚴重感染和由多重耐藥銅綠假單胞菌引起的感染存在特殊需求。

市場按藥物類型分為四類：頭孢菌素類、氨基糖甘類、碳青黴烯類、單環內□胺類等。頭孢菌素對某些銅綠假單胞菌菌株有效，並且已知這種細菌對許多頭孢菌素具有內在耐藥性，尤其是第一代頭孢菌素。值得一提的是，有

市場按給藥途徑分為三類：鼻腔、口服和靜脈注射。靜脈注射在市場上佔據主導地位，預計在預測期內將保持其主導地位。這是由於靜脈給藥途徑藥物的可用性和給藥發生率高。

市場按分銷渠道分為三類：醫院藥房、零售藥房和網上藥房。醫院在市場中佔據主導地位，預計在預測期內將保持其主導地位。 醫院在銅綠假單胞菌感染的診斷、治療和預防中發揮著重要作用。我們擁有資源、專業知識和需要有效治療策略來控制這些感染的患者群體。

銅綠假單胞菌感染治療市場 - 地理洞察

從地理上看，該市場遍布北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些地區根據引入業務的國家進一步劃分。由於銅綠假單胞菌感染數量不斷增加，預計北美將主導銅綠假單胞菌治療市場的增長。由於合併症增加、導尿管和飼管等侵入性裝置的存在、涉及抗生素的多重用藥以及與年齡相關的免疫力下降，老年人可能特別容易受到銅綠假單胞菌感染。據美國疾病控制與預防中心稱，2017 年，多重耐藥銅綠假單胞菌在美國造成約 32,600 例住院感染和約 2,700 人死亡。然而，預計亞太地區和歐洲在預測期內也將為銅綠假單胞菌治療市場提供顯著的增長機會。

銅綠假單胞菌感染治療市場-競爭格局：

銅綠假單胞菌感染治療市場競爭激烈，多家製藥公司提供抗生素和其他治療方案來對抗這些感染。製藥公司通過企業網站、電子商務網站、零售商、分銷商和最終消費者等多種渠道參與治療銅綠假單胞菌感染的抗生素的開發和營銷。此外，開發新抗生素和聯合療法來對抗銅綠假單胞菌新出現的耐藥性的能力對於在該市場保持競爭力至關重要。例如，Pfizer將於 2023 年將 SPR-206 投入臨床開發，目前正處於治療銅綠假單胞菌感染的 I 期臨床階段。根據Global Data的數據，針對銅綠假單胞菌的I期藥物的相變成功率（PTSR）為67%，這是進入II期的標誌。

最近的發展

Allergan最近宣布，美國食品和藥物管理局(FDA) 已批准AVYCAZ（頭孢他啶和阿維巴坦）用於治療複雜性尿路感染(cUTI)，並宣布已收到尋求擴大治療適應症的補充新藥申請(sNDA)複雜性腹腔內感染（cIAI）。

研究的主要特點

  • 本研究報告以2022年為基準年，提供了銅綠假單胞菌治療市場的市場規模、複合年增長率、估計和預測（2023-2030年）。
  • 該研究報告為客戶提供了銅綠假單胞菌治療市場的最新進展和見解。
  • 該研究報告闡明了不同細分市場/國家的潛在增長機會，並說明了銅綠假單胞菌感染治療市場有吸引力的投資主張矩陣。
  • 它確定了銅綠假單胞菌治療市場的新興投資機會、現有企業面臨的挑戰以及持續增長動力。
  • 研究報導詳細討論了 COVID-19 對銅綠假單胞菌感染治療市場規模、預測、複合年增長率和市場動態的影響。還涵蓋了對新冠肺炎後銅綠假單胞菌治療市場的深入見解。
  • 為了向本報告的用戶提供銅綠假單胞菌感染治療市場的全面了解，我們還包括了銅綠假單胞菌感染治療市場的競爭格局和關鍵創新者分析。
  • 該研究涵蓋了基於市場規模、增長率和吸引力對所有行業領域進行基準測試的增長前景映射分析。
  • 提供主要市場進入者的詳細公司概況，以幫助您了解在銅綠假單胞菌治療市場運營的公司的財務信息和戰略舉措。
  • 此外，報告還揭示了市場主要進入者不僅在全球層面而且在區域層面的重大收購和兼併、聯盟和合資企業、新產品推出、研發和區域擴張。
  • 全球銅綠假單胞菌治療市場報告主要面向該行業的各個利益相關者，如供應商、投資者、新進入者、分銷商和財務分析師。

目錄

第一章 銅綠假單胞菌感染治療市場概述

  • 調查範圍

第二章執行摘要

  • 市場細分
  • 競爭考慮

第三章銅綠假單胞菌感染治療的主要市場趨勢

  • 銅綠假單胞菌治療市場驅動因素
  • 銅綠假單胞菌治療市場製約因素
  • 銅綠假單胞菌藥物的市場機會
  • 銅綠假單胞菌藥物市場的未來趨勢

第四章 銅綠假單胞菌感染治療行業調查

  • PEST分析
  • 波特五力分析
  • 繪製增長前景
  • 監管框架分析

第五章銅綠假單胞菌感染治療市場：COVID-19 的影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析

第六章 銅綠假單胞菌感染治療市場格局

  • 2022 年銅綠假單胞菌治療市場份額分析
  • 主要製造商的細分數據
    • 已成立公司分析
    • 啟動分析

7. 銅綠假單胞菌感染治療市場 - 按藥物類型

  • 概述
    • 按藥品類型劃分的細分市場份額分析
    • 頭孢類
    • 氨基糖甘類
    • 碳青黴烯類
    • 內□胺
    • 其他

8. 銅綠假單胞菌感染治療市場-按給藥途徑分類

  • 概述
    • 按給藥途徑劃分的細分市場份額分析
    • 鼻子
    • 口服
    • 靜脈

9. 銅綠假單胞菌感染治療市場-按分銷渠道

  • 概述
    • 按銷售渠道劃分的細分市場份額分析
    • 醫院藥房
    • 零售藥店
    • 網上藥店

10 銅綠假單胞菌感染治療市場 – 按地區

  • 介紹
  • 北美
    • 概述
    • 銅綠假單胞菌感染性藥物北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要銅綠假單胞菌藥物製造商
    • 德國
    • 意大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 其他
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區銅綠假單胞菌藥物主要生產商
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳大利亞
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲一家主要的銅綠假單胞菌藥物製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲
    • 概述
    • 中東和非洲銅綠假單胞菌藥品主要生產商
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

11.主要供應商分析-銅綠假單胞菌處理行業

  • 比賽儀表板
  • 公司簡介
    • Allergan
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AstraZeneca PLC
    • Novartis AG
    • Lupin Pharmaceuticals Inc.
    • EnBiotix Inc
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Co.
    • Humanigen Inc
    • 其他

第十二章 分析師的全面看法

Product Code: ANV1288

REPORT HIGHLIGHT

Pseudomonas aeruginosa infection treatment Market size was valued at USD 1,607.8 million in 2022, expanding at a CAGR of 6.8% from 2023 to 2030.

Pseudomonas aeruginosa infections are generally treated with antibiotics. However, due to the bacterium's ability to develop resistance, selecting appropriate antibiotics can be challenging. Pseudomonas aeruginosa has been known to develop resistance to various antibiotics, an including those commonly used to treat infections. However, certain antibiotics, such as polymyxins can still be effective against multidrug-resistant strains. Additionally, newer antibiotics and alternative therapies, such as bacteriophages and monoclonal antibodies, are being explored as potential treatment options for multidrug-resistant Pseudomonas aeruginosa infections.

Pseudomonas aeruginosa infection treatment Market- Market Dynamics

Increasing consumer awareness about Pseudomonas aeruginosa infection treatment to propel market demand

Increasing consumer awareness about Pseudomonas aeruginosa infection treatment can certainly have a positive impact on market demand for related products and services. increasing consumer awareness can also adoptive interest and investment in research and development efforts to combat Pseudomonas aeruginosa infections. Consumer awareness can also lead to increased demand for supportive care and patient engagement services. The demand for Pseudomonas aeruginosa infection treatment is driven by several factors, including the increasing prevalence of Pseudomonas aeruginosa infections, rising antibiotic resistance, and others. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections identified that Pseudomonas aeruginosa (PA) is responsible for 10-15% of nosocomial infections worldwide.

Pseudomonas aeruginosa infection treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global Pseudomonas aeruginosa infection treatment market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
  • The Pseudomonas aeruginosa infection treatment industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on treatment segmentation, Combination Therapy was predicted to show maximum market share in the year 2022
  • Based on drug type segmentation, Cephalosporin was the leading type in 2022
  • Based on Route of Administration segmentation, Intravenous was the leading type in 2022
  • Based on distribution channels segmentation, Hospitals was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Pseudomonas aeruginosa infection treatment Market- Segmentation Analysis:

The Global Pseudomonas aeruginosa infection treatment Market is segmented on the basis of treatment type, drug type, route of administration, distribution channel, and Region.

The market is divided into three categories based on treatment type: Monotherapy and Combination Therapy. Combination Therapy dominates the market. It is particularly in demand for the treatment of severe infections or infections caused by multidrug-resistant strains of Pseudomonas aeruginosa.

The market is divided into four categories based on drug type: Cephalosporin, Aminoglycoside, Carbapenem, Monobactam, and Others. Cephalosporin propels market growth, due to It can be effective against certain strains of Pseudomonas aeruginosa, it's worth mentioning that this bacterium is known to be inherently resistant to many cephalosporin's, especially the first-generation cephalosporin's.

The market is divided into three categories based on the Route of Administration: Nasal, Oral, and Intravenous. Intravenous dominates the market and is likely to maintain its dominance during the forecast period, due to the availability of drugs for the Intravenous route, and high occurrence in dosing.

The market is divided into three categories based on distribution channels: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospitals dominate the market and are likely to maintain their dominance during the forecast period. It plays a crucial role in diagnosing, treating, and preventing Pseudomonas aeruginosa infections. They have the resources, expertise, and patient population that necessitate effective treatment strategies for managing these infections.

Pseudomonas aeruginosa infection treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the Pseudomonas aeruginosa infection treatment Market, due to a rise in the number of Pseudomonas aeruginosa infections. The elderly population may be particularly disposed to pseudomonad infection as a result of increased co-morbidities, the presence of invasive devices such as urinary catheters and feeding tubes, and polypharmacy that includes antibacterial, and immune compromise related to age. According to the center for disease control and Prevention, in 2017, multidrug-resistant Pseudomonas aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States. However, Asia Pacific and Europe are also expected to offer substantial growth opportunities for the Pseudomonas aeruginosa infection treatment market during the forecast period.

Pseudomonas aeruginosa infection treatment Market- Competitive Landscape:

The treatment market for Pseudomonas aeruginosa infections is competitive, with several pharmaceutical companies offering antibiotics and other therapeutic options to combat these infections. pharmaceutical companies involved in the development and marketing of antibiotics for Pseudomonas aeruginosa infections through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Additionally, the ability to develop new antibiotics or combination therapies to address emerging drug resistance in Pseudomonas aeruginosa is crucial for maintaining competitiveness in this market. For example, in 2023, SPR-206 is under clinical development by Pfizer and is currently in Phase I for Pseudomonas aeruginosa Infections. According to Global Data, Phase I drugs for Pseudomonas aeruginosa Infections has a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Recent Developments:

Allergan plc recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.

Key features of the study:

  • This proposed research study on Pseudomonas aeruginosa infection treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Pseudomonas aeruginosa infection treatment market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Pseudomonas aeruginosa infection treatment market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Pseudomonas aeruginosa infection treatment market
  • Impact of COVID-19 on Pseudomonas aeruginosa infection treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Pseudomonas aeruginosa infection treatment market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Pseudomonas aeruginosa infection treatment market, we have also included competitive landscape and key innovator analysis for the Pseudomonas aeruginosa infection treatment market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Pseudomonas aeruginosa infection treatment market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Pseudomonas aeruginosa infection treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET KEY PLAYERS

  • Allergan
  • Pfizer Inc.
  • Merck & Co. Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Lupin Pharmaceuticals Inc.
  • EnBiotix Inc
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Co.
  • Humanigen Inc
  • Other

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE

  • Monotherapy
  • Combination Therapy

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE

  • Cephalosporin
  • Aminoglycoside
  • Carbapenem
  • Monobactam
  • Others

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • Nasal
  • Oral
  • Intravenous

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

TABLE OF CONTENT

1. Pseudomonas aeruginosa infection treatment Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pseudomonas aeruginosa infection treatment Market Snippet by Drug Type
    • 2.1.2. Pseudomonas aeruginosa infection treatment Market Snippet by Route of Administration
    • 2.1.3. Pseudomonas aeruginosa infection treatment Market Snippet by Distribution channels
    • 2.1.4. Pseudomonas aeruginosa infection treatment Market Snippet by Country
    • 2.1.5. Pseudomonas aeruginosa infection treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Pseudomonas aeruginosa infection treatment Key Market Trends

  • 3.1. Pseudomonas aeruginosa infection treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pseudomonas aeruginosa infection treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pseudomonas aeruginosa infection treatment Market Opportunities
  • 3.4. Pseudomonas aeruginosa infection treatment Market Future Trends

4. Pseudomonas aeruginosa infection treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pseudomonas aeruginosa infection treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Pseudomonas aeruginosa infection treatment Market Landscape

  • 6.1. Pseudomonas aeruginosa infection treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pseudomonas aeruginosa infection treatment Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2022 & 2030 (%)
    • 7.1.2. Cephalosporin
    • 7.1.3. Aminoglycoside
    • 7.1.4. Carbapenem
    • 7.1.5. Monobactam
    • 7.1.6. Others

8. Pseudomonas aeruginosa infection treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 8.1.2. Nasal
    • 8.1.3. Oral
    • 8.1.4. Intravenous

9. Pseudomonas aeruginosa infection treatment Market - By Distribution channels

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution channels, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacy
    • 9.1.3. Retail Pharmacy
    • 9.1.4. Online Pharmacy

10. Pseudomonas aeruginosa infection treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Pseudomonas aeruginosa infection treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Allergan
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Merck & Co. Inc.
    • 11.2.4. AstraZeneca PLC
    • 11.2.5. Novartis AG
    • 11.2.6. Lupin Pharmaceuticals Inc.
    • 11.2.7. EnBiotix Inc
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Bristol-Myers Squibb Co.
    • 11.2.10. Humanigen Inc
    • 11.2.11. Other

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Pseudomonas aeruginosa infection treatment Market: Drug Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Type
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Drug Type 2018-2030 (USD Million)
  • TABLE Pseudomonas aeruginosa infection treatment Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Pseudomonas aeruginosa infection treatment Market: Regional snapshot (2022)
  • TABLE Pseudomonas aeruginosa infection treatment Market: Distribution channels Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution channels
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Distribution channels 2018-2030 (USD Million)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)